The bispecific antibody linvoseltamab introduces a patient-centric advancement, with its response-adapted dosing regimen, a flexible approach that aims to reduce the treatment burden for patients ...
Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback